Start-Up Quarterly Statistics, Q3 2014
This article was originally published in Start Up
Executive Summary
Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.
You may also be interested in...
Cancer Immunotherapy Reaches A Tipping Point
Now that it is clear the immune system can kill cancer, all kinds of companies are obsessed with the idea. Start-ups are tailoring business models to divergent technologies and market dynamics.
GSK’s Venture Deal With Avalon Yields Three Start-Ups In Two Years
Silarus Therapeutics and Thyritope Biosciences are the latest two companies to be launched and financed by GlaxoSmithKline and partner Avalon Ventures. During Informa’s Pharmaceutical Strategy Conference, GSK’s Lon Cardon talks about how the partnership with Avalon is helping the Big Pharma access academic science.
Infinity Gets More Than A Cash Boost With AbbVie Tie-Up
In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.